$RDNT

Forthuber Stephen M sold $2.6M of RDNT

Forthuber Stephen M (Pres & CEO-Eastern Operations) sold 44,067 shares of RadNet, Inc. (RDNT) at an average of $58.16 ($57.79–$58.61, $2.56M total) across 2 trades on 2026-06-15.

Original reporting
SEC EDGAR · Forthuber Stephen M
Published Jun 16, 2026, 8:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 16, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$RDNT
Bearish
medium confidence
Mentioned
$RDNT
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RDNTBearishLow
01

Why it matters

The disclosure provides a concrete, date-stamped insider sale amount and price range, which can influence short-term sentiment but does not introduce new operating or financial information.

02

Market read

Traders may monitor RDNT for continued insider selling or unusual volume, but the event alone is unlikely to drive a durable repricing.

03

What to watch

Because the article notes no 10b5-1 plan, traders may over-weight signal; also, insider sales can be tax-related and do not necessarily imply near-term earnings deterioration.

Relevance 6/10Novelty 6/10Timing: Filed 2026-06-16; sale executed 2026-06-15

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for RadNet, Inc.

Company-level read

Ticker impact

$RDNTBearishMedium confidence
Context

RadNet CEO-Eastern Operations sold $2.56M of RDNT shares via an open-market Form 4 on 2026-06-15 at ~$58.16 weighted avg.

Expected impact

Likely limited near-term impact; any effect should fade unless follow-on selling or other fundamentals emerge.

Evidence & confidence

The filing discloses a specific insider sale size/price and confirms it was not under a pre-arranged 10b5-1 plan, which can increase interpretive sensitivity, but it does not change guidance, contracts, or financial results.

Market effects

Minimal; this is company-specific insider activity with no sector-wide regulatory/earnings catalyst.

None indicated.

None indicated.

Counterpoint

The sale could be routine liquidity/portfolio rebalancing rather than a bearish view, especially since the filing provides no stated reason or linkage to fundamentals.

Key entities

  • RadNet, Inc.

    Subject of the Form 4 insider transaction; CEO-Eastern Operations sold shares on 2026-06-15.

  • Forthuber Stephen M

    Officer (Pres & CEO-Eastern Operations) who executed the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ABXMed

Barrick Profit Soars, Nvidia Eyes $500B AI Push, M&A Accelerates

The article reports multiple US corporate updates. Barrick Mining said Q2 profit rose 50% to $1.22B, with revenue up 44% to $5.29B, and agreed with Newmont on a $1.95B cash top-up to expand Nevada Gold Mines. Nvidia is working on a $500B AI financing venture; Intel announced a $15B stock offering. It also covers results for Axsome (revenue +46%), Monday.com, RadNet, NESR, and Camtek.

$RDNTHigh

RadNet, Inc. (RDNT): Results of Operations and Financial Condition

RadNet, Inc. (RDNT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA (1) and Revises Upwards 2026 Financial Guidance Ranges · Total Company Revenue increased 25.0% to a quarterly record of $622.7 million in the secon

$RDNTMed

DeepHealth Receives Two FDA Clearances Enabling it to Add Cardiovascular Insights and Prior Exam Integration to its AI-Powered Breast Suite

DeepHealth, a RadNet subsidiary (NASDAQ: RDNT), said it received two FDA 510(k) clearances for its Breast Suite: Breast Arterial Calcification (BAC) Assessment and prior-exam integration into ProFound Pro, to be marketed as Mammo Dx. Both are now commercially available in the U.S. DeepHealth reported BAC performance of >90% sensitivity and >88% specificity.